Zevaksyn (prademagene zamikeracel) — Coverage Criteria
Customize your policy alerts
Sign up for blue cross blue shield - south dakota Policy 05.05.96 alerts
Get alerted when Policy 05.05.96 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage and medical necessity determination for Zevaksyn (prademagene zamikeracel) for treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB)/recessive dystrophic epidermolysis bullosa (RDEB) for Blue Cross Blue Shield - South Dakota members.
No material clinical or coverage changes in this revision.
Coverage determination
Not Medically Necessary
Coverage stance
Policy-level denial for all indications
This policy applies only when benefits exist under the member's contract and any applicable exclusions, limitations, or exceptions have been considered. Benefit determinations are based on the contract language in effect at the time services are rendered and individual member benefits must be verified prior to prior authorization or claim submission. The policy may not apply to Federal Employee Program (FEP) members; FEP benefits are determined by the Federal Employee Program.
Zevaksyn (prademagene zamikeracel) is addressed by this policy for treatment of wounds in members with dystrophic epidermolysis bullosa. Per the coverage stance in this document, Zevaksyn is considered not medically necessary for all indications; therefore coverage and medical necessity determinations will reflect that stance unless contract language explicitly provides otherwise.
Zevaksyn (prademagene zamikeracel) is considered not medically necessary for all indications by this policy. The rationale stated in the policy is that there is insufficient evidence to determine clinical efficacy, along with inconsistent clinical trial results, important safety concerns, and overall uncertainty of the risk–benefit profile. As a result, requests for Zevaksyn will be evaluated in the context of this determination and the member's contract benefits.
Billing and coding guidance
Provider responsibilities and prior authorization
Confirm benefits and request prior authorization when applicable
Verify member benefits and obtain any required prior authorization or benefit determination before proceeding; coverage depends on the member's contract and whether benefits exist for the requested service.
- Benefits vary by contract; individual member benefits must be verified.
- Wellmark determines medical necessity only if the benefit exists and no contract exclusions apply.
Provider must verify benefits and medical necessity before treatment
Confirm member eligibility and benefit coverage and obtain prior authorization or benefit determination as required by the member's contract; do not assume coverage for Zevaksyn because the policy deems the product not medically necessary for all indications.
- Verify individual member benefits prior to services.
- If benefits exist, Wellmark will determine medical necessity; policy states Zevaksyn is considered not medically necessary for all indications.
Use appropriate CPT/HCPCS/revenue/ICD codes; unclassified HCPCS codes listed
Report services using appropriate procedure, diagnostic, and revenue codes; when reporting the product or related biologic/drug charges, use listed unclassified HCPCS codes as applicable.
Denial risk — policy-level not medically necessary determination
Zevaksyn is considered not medically necessary for all indications; submitting claims without prior benefit verification or for clinical indications outside of covered benefits risks denial.
- Policy-level determination: Zevaksyn not medically necessary for all indications due to insufficient evidence and safety concerns.
- Benefits must be verified per contract; Wellmark will not determine medical necessity if benefits do not exist, which may lead to claim denial.
Clinical background
Zevaksyn (prademagene zamikeracel) is an autologous, cell-based gene therapy manufactured from a patient's own genetically modified skin cells to express functional type VII collagen and is surgically grafted onto chronic wounds. The FDA approval was supported by the Phase III VIITAL randomized intrapatient-controlled trial in participants with COL7A1-related recessive dystrophic epidermolysis bullosa (RDEB), which evaluated wound healing and symptom outcomes. Despite demonstrated improvements in wound closure and pain in the trial, the policy cites uncertainty about long-term durability and safety as a key limitation to concluding a favorable risk–benefit profile.
Key definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.